ixazomib
ixazomib: 6 clinical trials tracked.
ixazomib evidence translation
What we can confirm
6 tracked trials
What it means
What to watch
Prepared research question
What is verified about ixazomib, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (6)
A Safety Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis
Primary endpoint: Dose limiting toxicity rate
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)
Primary endpoint: Progression Free Survival (PFS)
Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment With Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy
Primary endpoint: Symptomatic Myeloma Progression Free-survival (PFS) Rate
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma
Primary endpoint: Phase 1 (Dose-escalation): Maximum Tolerated Dose (MTD)
Phase II Randomized Trial of Continuation of Post-Transplant Maintenance With Single-Agent Lenalidomide vs. Consolidation/Maintenance With Ixazomib-Lenalidomide-Dexamethasone in Patients With Residual Myeloma
Primary endpoint: Percentage of Participants With MRD Negativity
A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Primary endpoint: Percentage of Participants With Overall Hematologic Response